In vivo characterization of several rodent glioma models by 1H MRS

NMR in Biomedicine

Volumn 25, Issue 4, 2012, Pages 685-694

  Doblas, Sabrina ^a,f   He, Ting ^a,b   Saunders, Debra ^a   Hoyle, Jessica ^c   Smith, Nataliya ^a   Pye, Quentin ^a   Lerner, Megan ^d   Jensen, Randy L ^e   Towner, Rheal A ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b Oklahoma Center for Neuroscience   (United States)

^c UNIVERSITY OF OKLAHOMA TULSA   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

1H MRS; Glioblastoma; Metabolic profile; Necrosis; Rodent glioma models

Indexed keywords

1H MRS; APPROPRIATE MODELS; ASPARTATES; ATHYMIC; GLIOBLASTOMAS; GUANOSINES; IN-VIVO; METABOLIC PROFILES; N-ACETYLASPARTATE; NECROSIS; PULSE POWER; WATER SUPPRESSION;

AMINO ACIDS; BIOMOLECULES; LIPIDS; METABOLISM; METABOLITES; RATS; WATER VAPOR;

TUMORS;

ASPARTIC ACID; CHOLINE; CREATINE; ETHYLNITROSOUREA; GLUTAMIC ACID; GLUTAMINE; GUANOSINE; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROMOLECULE; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PULSE RATE; RAT; SPECTROSCOPY; VARIABLE PULSE POWER AND OPTIMIZED RELAXATION DELAY;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DIAGNOSIS, COMPUTER-ASSISTED; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; PROTONS; RATS; RATS, INBRED F344; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

MUS; RATTUS; RODENTIA;

EID: 84858862686     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1785     Document Type: Article

References (71)

1. Central Brain Tumor Registry of the United States (CBTRUS). Statistical Report: Primary Brain Tumors in the United States, 2000-2004. CBTRUS: Hinsdale, IL; 2008 1-62.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.
3. Gudinaviciene I, Pranys D, Juozaityte E. Impact of morphology and biology on the prognosis of patients with gliomas. Medicina (Kaunas) 2004; 40: 112-120.
4. Fan G, Sun B, Wu Z, Guo Q, Guo Y. Invivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin. Radiol. 2004; 59: 77-85.
5. Vuori K, Kankaanranta L, Hakkinen AM, Gaily E, Valanne L, Granstrom ML, Joensuu H, Blomstedt G, Paetau A, Lundbom N. Low-grade gliomas and focal cortical developmental malformations: differentiation with proton MR spectroscopy. Radiology 2004; 230: 703-708.
6. 1H MRS of glial brain tumors: correlation with tissue histology and invitro MRS. Int. J. Oncol. 1998; 12: 461-468.
7. 1H) MR spectroscopy for routine diagnostic evaluation of brain lesions. Acta Radiol. 1997; 38: 953-960.
8. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002; 222: 715-721.
9. Kaminogo M, Ishimaru H, Morikawa M, Ochi M, Ushijima R, Tani M, Matsuo Y, Kawakubo J, Shibata S. Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain. Neuroradiology 2001; 43: 353-363.
10. Young GS. Advanced MRI of adult brain tumors. Neurol. Clin. 2007; 25: 947-973, viii.
11. Bernstein M, Parrent AG. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J. Neurosurg. 1994; 81: 165-168.
12. Soo TM, Bernstein M, Provias J, Tasker R, Lozano A, Guha A. Failed stereotactic biopsy in a series of 518 cases. Stereotactic Funct. Neurosurg. 1995; 64: 183-196.
13. Alesch F, Armbruster C, Budka H. Diagnostic value of stereotactic biopsy of cerebral lesions in patients with AIDS. Acta Neurochir. 1995; 134: 214-219.
14. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat. Rec. 2001; 265: 54-84.
15. Sibtain NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin. Radiol. 2007; 62: 109-119.
16. Moller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U, Zanella FE. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology, 2002; 44: 371-381.
17. 1H MR spectroscopy of brain tumours and masses. NMR Biomed. 2003; 16: 123-131.
18. Terpstra M, High WB, Luo Y, de Graaf RA, Merkle H, Garwood M. Relationships among lactate concentration, blood flow and histologic profiles in rat C6 glioma. NMR Biomed. 1996; 9: 185-194.
19. 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed. 1994; 7: 149-155.
20. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neurooncol. 1998; 36: 91-102.
21. Kish PE, Blaivas M, Strawderman M, Muraszko KM, Ross DA, Ross BD, McMahon G. Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: a model for experimental therapeutics of low-grade gliomas. J. Neurooncol. 2001; 53: 243-257.
22. Koestner A. Characterization of N-nitrosourea-induced tumors of the nervous system; their prospective value for studies of neurocarcinogenesis and brain tumor therapy. Toxicol. Pathol. 1990; 18: 186-192.
23. Grobben B, De Deyn PP, Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 2002; 310: 257-270.
24. Weizsaecker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, Barker M. The 9L rat brain tumor: description and application of an animal model. J. Neurol. 1981; 224: 183-192.
25. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 2006; 12: 6144-6152.
26. Szatmari T, Lumniczky K, Desaknai S, Trajcevski S, Hidvegi EJ, Hamada H, Safrany G. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 2006; 97: 546-553.
27. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM, Cavenee WK. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 1996; 93: 8502-8507.
28. Sibenaller ZA, Etame AB, Ali MM, Barua M, Braun TA, Casavant TL, Ryken TC. Genetic characterization of commonly used glioma cell lines in the rat animal model system. Neurosurg. Focus., 2005; 19: E1-E9.
29. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 1993; 53: 5822-5827.
30. Groothuis DR, Fischer JM, Pasternak JF, Blasberg RG, Vick NA, Bigner DD. Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. Cancer Res. 1983; 43: 3368-3373.
31. Hensley K, Abdel-Moaty H, Hunter J, Mhatre M, Mou S, Nguyen K, Potapova T, Pye QN, Qi M, Rice H, Stewart C, Stroukoff K, West M. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J. Neuroinflammation 2006; 3: 2-10.
32. von Kienlin M, Ziegler A, Le Fur Y, Rubin C, Decorps M, Remy C. 2D-spatial/2D-spectral spectroscopic imaging of intracerebral gliomas in rat brain. Magn. Reson. Med. 2000; 43: 211-219.
33. Rubenstein M, Shaw M, Mirochnik Y, Slobodskoy L, Glick R, Lichtor T, Chou P, Guinan P. Invivo establishment of T98G human glioblastoma. Methods Find Exp. Clin. Pharmacol. 1999; 21: 391-393.
34. Doblas S, Saunders D, Kshirsagar P, Pye Q, Oblander J, Gordon B, Kosanke S, Floyd RA, Towner RA. Phenyl-tert-butylnitrone induces tumor regression and decreases angiogenesis in a C6 rat glioma model. Free Radic. Biol. Med. 2008; 44: 63-72.
35. 1H NMR spectroscopy of rat brain at 1ms echo time. Magn. Reson. Med. 1999; 41: 649-656.
36. Gruetter R. Automatic, localized invivo adjustment of all first- and second-order shim coils. Magn. Reson. Med. 1993; 29: 804-811.
37. Reynolds G, Wilson M, Peet A, Arvanitis TN. An algorithm for the automated quantitation of metabolites in in vitro NMR signals. Magn. Reson. Med. 2006; 56: 1211-1219.
38. Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC. A constrained least-squares approach to the automated quantitation of in vivo (1)H magnetic resonance spectroscopy data. Magn. Reson. Med. 2011; 65: 1-12.
39. Cudalbu C, Cavassila S, Rabeson H, van Ormondt D, Graveron-Demilly D. Influence of measured and simulated basis sets on metabolite concentration estimates. NMR Biomed. 2008; 21: 627-636.
40. Pfeuffer J, Tkac I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J. Magn. Reson. 1999; 141: 104-120.
41. 1H-MR spectra in the presence of mobile lipids. Magn. Reson. Med. 2001; 46: 615-618.
42. 1H magnetic resonance spectroscopy and imaging. NMR Biomed. 2010; 23: 624-632.
43. Doblas S, He T, Saunders D, Pearson J, Hoyle J, Smith N, Lerner M, Towner RA. Glioma morphology and tumor-induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography. J. Magn. Reson. Imaging 2010; 32: 267-275.
44. Jenkinson MD, Smith TS, Joyce K, Fildes D, du Plessis DG, Warnke PC, Walker C. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 2005; 64: 2085-2089.
45. Dowling C, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, Day MR, Henry RG, Chang SM, Dillon WP, Nelson SJ, Vigneron DB. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. Am. J. Neuroradiol. 2001; 22: 604-612.
46. 1H MRS invivo in brain tumors: experience of the Siemens cooperative clinical trial. Anticancer. Res. 1996; 16: 1533-1538.
47. Rémy C, Arús C, Ziegler A, Lai ES, Moreno A, Le Fur Y, Décorps M. Invivo, exvivo, and invitro one- and two-dimensional nuclear magnetic resonance spectroscopy of an intracerebral glioma in rat brain: assignment of resonances. J. Neurochem. 1994; 62: 166-179.
48. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 2000; 80: 1107-1213.
49. Oshiro S, Tsugu H, Komatsu F, Abe H, Onishi H, Ohmura T, Iwaasa M, Sakamoto S, Fukushima T. Quantitative assessment of gliomas by proton magnetic resonance spectroscopy. Anticancer. Res. 2007; 27: 3757-3763.
50. Catalaa I, Henry R, Dillon WP, Graves EE, McKnight TR, Lu Y, Vigneron DB, Nelson SJ. Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. NMR Biomed. 2006; 19: 463-475.
51. 1H-magnetic resonance spectroscopy: correlation with histopathology and immunohistochemistry. Neuroradiology 2006; 48: 312-318.
52. Central Brain Tumor Registry of the United States (CBTRUS). Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2005. CBTRUS: Hinsdale, IL; 2009
53. Struikmans H, Rutgers DH, Jansen GH, Tulleken CA, van der Tweel I, Battermann JJ. Prognostic relevance of cell proliferation markers and DNA-ploidy in gliomas. Acta Neurochir. 1998; 140: 140-147.
54. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 2007; 81: 89-131.
55. 1H magnetic resonance spectroscopy of an intracerebral rat glioma. Magn. Reson. Med. 1992; 23: 96-108.
56. 2 relaxation times of lipid and macromolecules: a study of high-grade tumor spectra. J. Magn. Reson. Imaging 2008; 27: 178-184.
57. Gotsis ED, Fountas K, Kapsalaki E, Toulas P, Peristeris G, Papadakis N. Invivo proton MR spectroscopy: the diagnostic possibilities of lipid resonances in brain tumors. Anticancer. Res. 1996; 16: 1565-1567.
58. 1H MR spectra: a comparison of classification using whole spectra versus metabolite quantification. NMR Biomed. 2007; 20: 763-770.
59. 1H magnetic resonance spectroscopy. Magn. Reson. Med. 2003; 49: 223-232.
60. Murphy PS, Rowland IJ, Viviers L, Brada M, Leach MO, Dzik-Jurasz AS. Could assessment of glioma methylene lipid resonance by invivo (1)H-MRS be of clinical value? Br. J. Radiol. 2003; 76: 459-463.
61. 1H nuclear magnetic resonance correspond to lipid droplets. Cancer Res. 1997; 57: 407-414.
62. 1H MRS during gene therapy-induced apoptosis: interrationships between water diffusion and mobile lipids. NMR Biomed. 2009; 22: 272-279.
63. Li X, Vigneron DB, Cha S, Graves EE, Crawford F, Chang SM, Nelson SJ. Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas invivo. Am. J. Neuroradiol. 2005; 26: 760-769.
64. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the invivo detection of apoptosis. Nat. Med. 1999; 5: 1323-1327.
65. 1H MRS invivo: effects of ganciclovir-induced apoptosis on lipids. FEBS Lett. 2006; 580: 4746-4750.
66. 1H HRMAS metabolite measurements in adult human gliomas. J. Magn. Reson. Imaging 2010; 31: 289-297.
67. Barth RF, Kaur B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J. Neurooncol. 2009; 94: 299-312.
68. Thorsen F, Jirak D, Wang J, Sykova E, Bjerkvig R, Enger PO, van der Kogel A, Hajek M. Two distinct tumor phenotypes isolated from glioblastomas show different MRS characteristics. NMR Biomed. 2008; 21: 830-838.
69. Gyngell ML, Els T, Hoehn-Berlage M, Hossmann KA. Proton MR spectroscopy of experimental brain tumors invivo. Acta Neurochir. Suppl. (Wien) 1994; 60: 350-352.
70. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY, Jensen RL. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 2008; 113: 1032-1042.
71. Stadlbauer A, Gruber S, Nimsky C, Fahlbusch R, Hammen T, Buslei R, Tomandl B, Moser E, Ganslandt O. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006; 238: 958-969.